Quick Answer
International Stem Cell CORP reported Revenue From Contract With Customer Excluding Assessed Tax of $9.10 million for the year ending 2025.
- International Stem Cell CORP showed an increase of +0.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from International Stem Cell CORP's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), International Stem Cell CORP's Revenue From Contract With Customer Excluding Assessed Tax has grown by 22.0%.
- Historical annual values: Fiscal year 2025: $9.10 million | Fiscal year 2024: $9.09 million | Fiscal year 2023: $7.79 million | Fiscal year 2022: $8.18 million | Fiscal year 2021: $7.18 million | Fiscal year 2020: $7.13 million | Fiscal year 2019: $9.47 million | Fiscal year 2018: $11.09 million | Fiscal year 2017: $7.46 million.
- Data sourced from SEC EDGAR public filings as of June 25, 2026.
Last verified: